Gilead Sciences, Inc. $GILD Shares Sold by Verity Asset Management Inc.

Verity Asset Management Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 49.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,357 shares of the biopharmaceutical company’s stock after selling 10,237 shares during the quarter. Verity Asset Management Inc.’s holdings in Gilead Sciences were worth $1,271,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in GILD. Massachusetts Financial Services Co. MA lifted its holdings in shares of Gilead Sciences by 3,763.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,223,304 shares of the biopharmaceutical company’s stock valued at $518,368,000 after acquiring an additional 4,113,999 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Gilead Sciences by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 121,097,336 shares of the biopharmaceutical company’s stock valued at $14,863,487,000 after acquiring an additional 2,113,692 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Gilead Sciences by 154.3% during the 3rd quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock valued at $342,910,000 after acquiring an additional 1,874,508 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company’s stock valued at $1,680,505,000 after acquiring an additional 1,618,453 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of Gilead Sciences by 46.7% during the 3rd quarter. Los Angeles Capital Management LLC now owns 3,845,379 shares of the biopharmaceutical company’s stock valued at $426,837,000 after acquiring an additional 1,223,895 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley raised its price target to $175 and kept an “overweight” rating, signaling large analyst upside that can attract buy-side interest and momentum flows. Morgan Stanley Adjusts Gilead Sciences Price Target to $175
• Positive Sentiment: The U.S. FDA accepted Gilead’s NDA for a once?daily bictegravir + lenacapavir HIV single?tablet regimen and granted priority review with an August PDUFA — a clear near-term regulatory catalyst that shortens the approval timeline if approved. U.S. FDA Grants Priority Review of New Drug Application for Gilead’s Once-Daily HIV Treatment
• Positive Sentiment: Gilead completed its ~$7.8B acquisition of Arcellx, adding the anito?cel cell therapy to its oncology pipeline — broadens growth optionality and potential future revenue streams. Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel
• Positive Sentiment: Gilead recently increased its quarterly dividend (annualized $3.28, ~2.5% yield), supporting income-oriented investor demand and underpinning valuation. MarketBeat GILD Profile
• Positive Sentiment: Technical commentary notes GILD is retesting a long-term breakout (an 11?year cup base) with analysts projecting ~35% upside if momentum holds — may draw technical buyers. Gilead Sciences Crosses Critical Breakout Level
• Neutral Sentiment: Erste Group issued small EPS estimate tweaks (slight FY2026 cut, FY2027 raise) — minor model revisions that mostly track consensus and aren’t a large directional shock. Erste Group Research Notes
• Neutral Sentiment: Macro/sector items (Amgen earnings focus; biotech ETF commentary) could affect sector flows into GILD but are not company?specific catalysts. FBT ETF Overview
• Negative Sentiment: CEO Daniel O’Day sold 10,000 shares under a pre-arranged 10b5-1 plan (~$1.29M) — routine but may be viewed negatively by some investors despite prior, larger planned sales. SEC Filing: Form 4
• Negative Sentiment: An advocacy group filed a shareholder resolution seeking more transparency on patent exclusivities — introduces governance/IP scrutiny that could create periodic headline risk. AHF’s Gilead Shareholder Resolution

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on GILD shares. The Goldman Sachs Group lifted their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Daiwa Securities Group lifted their target price on shares of Gilead Sciences from $129.00 to $161.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $118.00 to $123.00 and gave the company a “sector perform” rating in a report on Tuesday, April 7th. Oppenheimer boosted their price objective on shares of Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Finally, Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $157.35.

Insider Transactions at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the sale, the chief executive officer owned 632,567 shares of the company’s stock, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer directly owned 176,191 shares of the company’s stock, valued at $24,835,883.36. The trade was a 1.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 178,640 shares of company stock valued at $26,584,250. Insiders own 0.30% of the company’s stock.

Gilead Sciences Stock Up 2.1%

GILD stock traded up $2.68 during trading on Thursday, reaching $131.52. The stock had a trading volume of 536,420 shares, compared to its average volume of 6,720,214. Gilead Sciences, Inc. has a 1-year low of $95.29 and a 1-year high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $163.24 billion, a P/E ratio of 19.41, a PEG ratio of 1.69 and a beta of 0.39. The firm has a fifty day moving average price of $140.90 and a 200 day moving average price of $132.36.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm had revenue of $7.93 billion for the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the previous year, the business posted $1.90 EPS. The firm’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, March 30th. Stockholders of record on Friday, March 13th were given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend was Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s payout ratio is presently 48.45%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.